Vaxxinity’s cholesterol vaccine reduces LDL in primates

Vaxxinity's cholesterol vaccine reduces LDL in primates

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Promising preclinical results for cholesterol vaccine candidate boost hopes for treatment and prevention of heart disease.

Immunotherapeutic vaccine developer Vaxxinity has published promising preclinical data for its cholesterol vaccine candidate, VXX-401. The findings, published in the Journal of Lipid Research, demonstrate the vaccine reproducibly reduced low-density lipoprotein cholesterol (LDL-C) in non-human primates.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2449

Vaxxinity

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Vaxxinity is a clinical-stage biotechnology company developing a proprietary platform of synthetic peptide vaccines designed to harness the immune system for treating chronic and infectious diseases. The company's Vaxxine Platform technology stimulates selective immune activation to overcome immune tolerance, converting the body into a natural antibody-producing system. Vaxxinity's pipeline targets neurodegenerative diseases including Alzheimer's disease and Parkinson's disease, as well as cardiovascular conditions such as hypercholesterolemia and infectious diseases including COVID-19, with the overarching mission to democratize global healthcare by making effective immunotherapies accessible and affordable worldwide.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE